Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
Frontiers in Pharmacology · 19.12.2024 · 15
DOI: 10.3389/fphar.2024.1509319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2024. Verfasst von Wei Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.
Methods
A fast ultra-high performance liquid chromatography-tandem quadrupole mass spectrometry method was developed for the determination of MRTX1133 in rat plasma, tissue homogenate, and urine. The method applied to the pharmacokinetics, bioavailability, tissue distribution, and excretion of MRTX1133 after oral administration (25 mg/kg) and intravenous administration (5 mg/kg).
Results
The calibration curve for MRTX1133 in plasma and other homogenates was linear, with r 2 > 0.99. The intra- and inter-day accuracies were ranged from 85% to 115% and precision were within ± 10%. The matrix effect and recovery were within ± 15 %. The Cmax of MRTX1133 was 129.90 ± 25.23 ng/mL at 45 min after oral administration. The plasma half-life (t 1/2 ) of MRTX1133 was 1.12 ± 0.46 h after oral administration and 2.88 ± 1.08 after intravenous administration. Its bioavailability was 2.92%. Furthermore, MRTX1133 was widely distributed in all the main organs, including liver, kidney, lung, spleen, heart, pancreas, and intestine. MRTX1133 was still detectable in liver, kidney, lung, spleen, heart, and pancreas after 24 h. The excretion ratio of prototype MRTX1133 through kidney was 22.59% ± 3.22% after 24 h.
Conclusions
MRTX1133 was quickly absorbed, and widely distributed in the main organs. This study provided a reference for the quantitative determination of MTRX1133 in preclinical or clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
- College of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, China.
- Department of Health Management, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Cardiovascular Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
- Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
- Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Zitieren
APA
Lu, W., Zeng, R., Pan, M., Zhou, Y., Tang, H., Shen, W., Tang, Y., & Lei, P. (2024). Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1509319
Vancouver
Lu W, Zeng R, Pan M, Zhou Y, Tang H, Shen W, et al. Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1509319
BibTeX
@article{Lu2024,
author = {Lu, Wei and Zeng, Rong and Pan, Meng and Zhou, Yuan and Tang, Huijuan and Shen, Wanying and Tang, Yijun and Lei, Pan},
title = {Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1509319}
}
EUVIMED